<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025632</url>
  </required_header>
  <id_info>
    <org_study_id>RA101495-02.202</org_study_id>
    <nct_id>NCT04025632</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ra Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ra Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of zilucoplan in patients&#xD;
      with Immune-Mediated Necrotizing Myopathy (IMNM). Subjects will be randomized in a 1:1 ratio&#xD;
      to receive daily SC doses of 0.3 mg/kg zilucoplan or matching placebo for 8 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No relevant safety differences between Zilucoplan and placebo were identified.&#xD;
  </why_stopped>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">March 4, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change from Baseline to Week 8 in Creatine Kinase (CK) Levels</measure>
    <time_frame>Baseline (Day 1) to Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience a Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Day 1 to up to 40 days after last dose (up to an overall duration of approximately 21 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieve at Least Minimal Response Based on the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Response Criteria Scale</measure>
    <time_frame>Baseline (Day 1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in Triple Timed Up and Go Test (3TUG) Time</measure>
    <time_frame>Baseline (Day 1) to Week 8</time_frame>
    <description>The 3TUG test will only be performed in participants who are ambulatory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in Proximal Manual Muscle Testing (MMT) Grade</measure>
    <time_frame>Baseline (Day 1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in Physician Global Activity Visual Analogue Scale (VAS) Score</measure>
    <time_frame>Baseline (Day 1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in Patient Global Activity Visual Analogue Scale (VAS) Score</measure>
    <time_frame>Baseline (Day 1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in Health Assessment Questionnaire (HAQ) Score</measure>
    <time_frame>Baseline (Day 1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in Myositis Disease Activity Assessment Tool (MDAAT) Extramuscular Disease Activity Visual Analogue Scale (VAS) Score</measure>
    <time_frame>Baseline (Day 1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score</measure>
    <time_frame>Baseline (Day 1) to Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Immune Mediated Necrotizing Myopathy</condition>
  <arm_group>
    <arm_group_label>0.3 mg/kg zilucoplan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily subcutaneous (SC) injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zilucoplan</intervention_name>
    <description>Daily subcutaneous (SC) inection</description>
    <arm_group_label>0.3 mg/kg zilucoplan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily subcutaneous (SC) inection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of IMNM (Immune-Mediated Necrotizing Myopathy)&#xD;
&#xD;
          -  Positive serology for anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) or&#xD;
             anti-signal recognition particle (SRP) autoantibodies&#xD;
&#xD;
          -  Clinical evidence of weakness (â‰¤ grade 4 out of 5) on manual muscle testing in at&#xD;
             least one proximal limb muscle group&#xD;
&#xD;
          -  Creatine kinase (CK) of &gt;1000 U/L at Screening&#xD;
&#xD;
          -  No change in corticosteroid dose for at least 30 days prior to Baseline or anticipated&#xD;
             to occur during the first 8-weeks on study&#xD;
&#xD;
          -  No changes in immunosuppressive therapy, including dose, for at least 30 days prior to&#xD;
             Baseline or anticipated to occur during the first 8-weeks on study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of meningococcal disease&#xD;
&#xD;
          -  Current or recent systemic infection within 2 weeks prior to Screening or infection&#xD;
             requiring intravenous (IV) antibiotics within 4 weeks prior to Screening&#xD;
&#xD;
          -  Recent initiation of intravenous immunoglobulin (IVIG) (i.e., first cycle administered&#xD;
             less than 90 days prior to Baseline)&#xD;
&#xD;
          -  Rituximab use within 90 days prior to Baseline or anticipated to occur during study&#xD;
&#xD;
          -  Statin use within 30 days prior to Baseline or anticipated to occur during study&#xD;
&#xD;
          -  Plasma exchange within 4 weeks prior to Baseline or expected to occur during the&#xD;
             8-week Treatment Period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health Neuroscience Institute</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Neurology Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Neuromuscular Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Universitaire PitiÃ© SalpÃªtriÃ¨re</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Barnes Clinical Research Facility</name>
      <address>
        <city>Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

